Drug Profile
IVR 103
Alternative Names: IVR-103Latest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator Ivrea Pharmaceuticals
- Class Antiacnes; Antineoplastics; Cyclohexenes; Keratolytics; Retinoids; Small molecules
- Mechanism of Action Retinoic acid receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Acne
Most Recent Events
- 25 Mar 2010 Discontinued - Clinical-Phase-Unknown for Acne in USA (Topical)
- 07 Feb 2007 Clinical trials in Acne in USA (Topical)